Importance The association between changes in atherosclerotic plaque induced by lipid-
lowering therapies (LLTs) and reduction in major adverse cardiovascular events (MACEs) …

Introduction Individuals diagnosed with atherosclerotic cardiovascular disease (ACD) are
exposed to an increased risk of cardiovascular events. Reducing low-density lipoprotein …

Background It remains controversial whether adding ezetimibe to low/moderate‐intensity
statins has a more beneficial impact on the treatment efficacy and safety of patients with …

Background Evidence indicates that the addition of ezetimibe to statin therapy reduces
cardiovascular events. However, the impact of ezetimibe–statin combination therapy on …

Lipid-lowering therapy plays a central role in reducing cardiovascular events. Over the past
few decades, clinical trials utilizing several imaging techniques have consistently shown that …

Симпозиум «Атеросклеротическая рапсодия» состоялся в рамках X Международного
образовательного форума «Российские дни сердца» в Санкт-Петербурге. На …

Aim Statin therapy is considered the gold standard for treating hypercholesterolemia. This
updated meta-analysis aims to compare the efficacy and safety of a low/moderate-intensity …

Background Atherosclerotic cardiovascular disease (ASCVD), affects approximately 18.6
million individuals worldwide and poses a significant healthcare related challenge. Despite …

Lipid-lowering therapy is undoubtedly the most essential part of treating atherosclerotic
cardiovascular diseases (CVD). However, even with aggressive lipid-lowering therapy, CVD …

Ezetimibe is an intestinal cholesterol/sterol inhibitor. It is generally well-tolerated, and except
for coadministration with cyclosporin (which increases concentration of both ezetimibe and …